Bogart Wealth LLC Grows Stake in Eli Lilly and Company $LLY

Key Points

• Bogart Wealth LLC significantly increased its holdings in Eli Lilly and Company by 1,775.7% during the second quarter, owning 9,116 shares worth approximately $7.1 million by the end of the period.
• Eli Lilly's stock opened at $803.53, with a 52-week high of $935.63 and a low of $623.78, reflecting strong market performance with a market capitalization of $760.51 billion.
$6.31 per share for the last quarter, exceeding expectations and marking a 37.6% year-over-year revenue increase to $15.56 billion.

Bogart Wealth LLC grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 1,775.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 9,116 shares of the company's stock after buying an additional 8,630 shares during the quarter. Bogart Wealth LLC's holdings in Eli Lilly and Company were worth $7,106,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. WestEnd Advisors LLC lifted its stake in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the 1st quarter valued at approximately $27,000. Citizens National Bank Trust Department increased its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC increased its position in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after buying an additional 31 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $803.53 on Monday. The stock has a 50-day simple moving average of $753.09 and a two-hundred day simple moving average of $765.70. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market capitalization of $760.51 billion, a PE ratio of 52.52, a P/E/G ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other news, EVP Daniel Skovronsky purchased 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. Guggenheim reaffirmed a "buy" rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday. Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a report on Sunday, August 17th. Berenberg Bank reissued a "hold" rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a report on Friday, October 10th. Finally, Morgan Stanley reduced their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $939.12.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.